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CHAPTER 1 
 
INTRODUCTION 
 
 
 
1. EQUINE OCULAR SQUAMOUS CELL CARCINOMA 
 
 Squamous cell carcinoma (SCC) is the most common neoplasm of the equine eye 
and ocular adnexa and the second most common tumor of the horse overall.1, 2  Ocular 
SCC may involve the corneoconjunctiva, bulbar conjunctiva, third eyelid and eyelids.3  
Biological behavior of SCC is reported to differ depending on location, but it is typically 
locally invasive with a potential to metastasize.  Poorer prognosis was associated with 
tumor located at the eyelid, compared to the third eyelid, nasal canthus or limbus in one 
study.4  Metastasis of ocular SCC to local lymph nodes, salivary glands, and lungs can 
occur.  Reported rates of metastasis for equine ocular SCC range from 6 to 15.4 %.5,6  
Local invasion of the tumor often accompanies ulcerative necrosis and inflammation 
resulting in significant ocular discomfort.   
 A variety of treatment modalities for equine SCC has been reported in case 
reports or case series with variable success.  Reported therapies include surgical 
excision7 , cryotherapy8, beta-irradiation9,10, radiofrequency hyperthermia11, intratumoral 
chemotherapy12, and interstitial radiotherapy.13  Recurrence rates within a year of 
treatment have been reported between 50-66.7% with surgery alone, and range from 15-
67% with surgery and ancillary irradiation or cryotherapy.3, 14  A 42.4 % recurrence rate 
for ocular SCC with surgical excision, radiofrequency hyperthermia or both has also been 
reported.6  In another study, treatments included surgical excision, surgical excision with 
90Sr beta irradiation, surgical excision with cryotherapy, surgical excision with 
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radiofrequency, surgical excision with 137Cs interstitial radiotherapy, and/or 
immunotherapy, and the overall recurrence rate was 30.4%.4  No single treatment 
modality has proven to be effective, and treatment complications commonly threaten both 
visual outcome and long term survival.  In an effort to preserve vision and comfort, much 
effort has been directed toward improving adjuvant therapy following surgical excision.  
However, ocular SCC in horses is a spontaneously occurring disease, and the use of 
horses to prospectively evaluate treatment response rates to new therapeutic modalities is 
both cost prohibitive and limited by animal numbers.  To date, a clinically relevant in 
vivo model for equine SCC does not exist.   
 
2. MURINE TUMOR MODEL 
 Murine tumor models which accurately reproduce spontaneous neoplasia play 
important roles in investigating tumor behavior, histological characteristics, and in 
evaluating efficacy of novel cancer treatments.  Studies using these models provide 
advantages of reproducibility of the neoplasia, low cost, ease of manipulation and time 
effectiveness.  Xenografts of animal tumors may represent metabolic characteristics of 
animal malignant disease and often have value in selecting tumor-specific agents when 
used as screening tools.15  Studies have shown that tumor xenografts in murine models 
demonstrate a significant correlation with clinically relevant response rates to various 
treatments.16  
 In veterinary oncology research, subcutaneous induction of tumor growth in mice 
has been described following xenotransplantation from dogs (mammary carcinoma17, 
non-small cell lung cancers18, mast cell tumor19, lymphomas20,21, transmissible venereal 
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tumor22,23, glioma23), cats (mammary carcinoma24, melanoma25), cows 
(lymphosarcoma26), and sheep (squamous cell carcinoma27).  Such transplants have been 
accomplished with either single-cell suspensions of established cell lines or direct 
surgical explants.  Reports of xenotransplantation of horse tumors are limited to a sarcoid 
derived cell line28 and an undifferentiated skin carcinoma.29  Cell lines of equine SCC 
have not been established to date.  Xenografts derived from cell lines generally show a 
homogeneous undifferentiated histology, due to selection of a cell population with 
repeated passages resulting in histologic changes from the original tumor.30  In contrast, 
xenografts established by implantation of fresh tumor tissue sections have been shown to 
more closely resemble the original patient specimens in their architecture and 
morphology.31,32  
 
3. TISSUE CRYOPRESERVATION 
 In human medicine, there is a rapidly growing interest in “tumor banking”, where 
small pieces of frozen tissues are preserved for possible future ancillary studies.  
Cryopreserved specimens offer readily available samples to be utilized in exploring novel 
cancer treatment options, genetic assays, chemosensitive assays, and tumor cell 
vaccines.33,34  Use of cryopreserved samples for xenotransplantation avoids the 
difficulties associated with cell cultures and continuous animal passage, including 
contamination, accidental loss, genetic mutation. 
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4. PHOTODYNAMIC THERAPY 
a. Overview 
 Photodynamic therapy (PDT) is an evolving modality for the treatment of a 
variety of ailments, including solid tumors, age-related macular degeneration, and 
atherosclerotic plaques.35-38  PDT involves the use of photochemical reactions mediated 
through the interaction of photosensitizing agents, light and oxygen.39,40   Photosensitizers 
are typically given intraveneously and are preferentially retained in neoplastic tissue. 40 
Upon activation by visible light matching the drug’s absorption spectrum, the excited 
photosensitizer reacts directly with organic substrates to produce free radicals or reacts 
with ground state triplet oxygen to generate singlet oxygen.39  This photodynamic process 
causes irreversible oxidation of one or more critical cellular components including 
plasma membranes, mitochondria, and lysosomes, inducing necrosis and apoptosis of the 
treated tissue.  PDT also induces oxidative damage to the microvasculature contributing 
to ischemic tumor death.40  Because a photosensitizer is preferentially absorbed by 
proliferative abnormal tissue and the light source is directly targeted on the lesion, PDT 
achieves highly selective treatment of a target area while minimizing damage to adjacent, 
healthy structures.  With the exception of transient cutaneous photosensitivity and some 
tissue swelling, PDT has no other known systemic toxic side effects and is not 
carcinogenic or mutagenic at the doses used clinically. 41,42 
 
b. Photochemistry of photodynamic therapy 
 A photosensitizer has no effect on tissue unless it is activated by light of the 
appropriate wavelength.  When the photosensitizer chromophore is illuminated with light 
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of the specific wavelength that matches the electronic absorption spectrum of the 
photosensitizer, it is excited to a singlet state.  Once it has absorbed energy in the form of 
electromagnetic radiation, it can return to ground state by a number of pathways.  The 
chromophore can relax back to the ground state, by emitting photons between the same 
spin states (fluorescence), or be converted to excited triplet states via internal conversion 
(IC) and intersystem crossing (ISC), which is a radiationless transition between different 
spin states during collisions with other molecules.  This reaction is represented by the 
Jablonski diagram (Figure 1).39   
 In oxygenated environments the triplet excited state photosensitizer (3P*) readily 
transfers its energy to ground state molecular oxygen 3O2 to produce singlet oxygen 1O2.  
These interactions of photosensitizers with molecular oxygen are known as Type-II 
reactions.  Once activated, an excited photosensitizer (3P*) can also react directly with 
organic substrates (S) by electron exchange producing an oxidized substrate (S+) and 
reduced photosensitizer (P-).  The excited photosensitizer (3P*) can also react with 
superoxide radicals (O2.) to produce superoxide anions (O2-) which can then create the 
highly reactive hydroxyl radical (OH.).  These reactions are called Type-I photoreactions. 
Type II reactions are reported to dominate during PDT.  However, Type-1 reactions may 
become more dominant under conditions where photosensitizers are highly concentrated, 
and especially under hypoxic conditions. 43  Singlet oxygen and free radicals generated 
through photochemical reactions are toxic to cells and tissues.  
c. Biological mechanisms of action 
 Most photosensitizers localize to cytosolic targets such as Golgi, endoplasmic 
reticulum, mitochondria, lysosomes, and membranes.44-46  Geze et al. suggested that 
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hydrolases and acid that leak out of the damaged lysosomes may degrade cellular 
components.47  Photosensitizers that localize to lysosomes may also re-localize to more 
susceptible organelles such as the membranes of the mitochondria or nuclei after rupture 
of lysosomes.48  Studies have shown that PDT results in inhibition of several 
mitochondrial proteins including malate dehydrogenase, succinate dehydrogenase, and 
cytochrome c oxidase.49  These proteins are required to maintain the electrochemical 
gradient across the inner-mitochondrial membrane.  Among these proteins, cytochrome c 
oxidase was inhibited to the greatest extent in one study.49  Another proposed target of 
PDT includes a protein complex termed permeability transition pore (PT pore).50  The 
complex consists of hexokinase, the peripheral benzodiazepine receptor, the voltage-
dependent anion channel, creatine kinase, the adenine nucleotide translocator and 
cyclophyllin D.50  As these permeability transition pores open in response to PDT, small 
molecules flow in and out of the mitochondrial matrix resulting in disruption of  
mitochondrial membrane potential and mitochondrial swelling.51  This process also 
results in breakdown of uncoupling electron transport chain and release of detrimental 
reactive oxygen species inducing apoptosis. 52,53  Reduced activity of adenosine 
triphosphatase (ATPase) has also been demonstrated with PDT.54  Damage to subcellular 
targets lead to rapid apoptosis and necrosis of tumor cells.  
 Vascular destruction is also considered to be an important mechanism of tumor 
death in vivo for most photosensitizers being investigated clinically.  Microscopically, 
the tumor tissue is characterized by endothelial cell damage, platelet aggregation, 
vasoconstriction, and hemorrhage following PDT.55-57 Damage to the vascular endothelial 
cells is believed to be associated with platelet activation and release of factors such as 
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eicosanoids, in particular thromboxane, histamines and tumor necrosis factor α.57-59  PDT 
may also lead to vessel constriction via inhibition of the production or release of nitric 
oxide by the endothelium.60  Microvascular collapse and thrombus formation lead to 
severe and persistent post-PDT tumor hypoxia/anoxia and may contribute to long-term 
tumor control. 57,61-64   
 A strong inflammatory reaction is also an important event in the mechanism of 
PDT-mediated tumor destruction.  Photooxidative lesions of membrane lipids prompt 
accelerated phospholipid degradation with a massive release of lipid fragments and 
metabolites of arachidonic acid, which act as powerful inflammatory mediators. 65 
Endothelial damage also leads to a massive release of various inflammatory mediators.66 
Potent inflammatory mediators released following PDT include vasoactive substances, 
components of the complement and clotting cascades, acute phase proteins, proteinases, 
peroxidases, radicals, leukocyte chemo-attractants, cytokines, growth factors and other 
immuno-regulators.66,67  Among cytokines, IL-6 mRNA and protein were found to be 
strongly enhanced in PDT treated mouse tumors.68  In response to the inflammatory 
signaling, large numbers of neutrophils, mast cells, and monocytes/macrophages invade 
the treated tissue during and after PDT.69  Lysosomal enzymes and reactive oxygen 
species secreted by neutrophils destroy endothelia and tumor cells and further amplify the 
inflammatory response.65,70   In addition, generation of immune memory cells sensitized 
to PDT-treated tumors is believed to contribute to long-term tumor control.40,71   
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d. Photosensitizer localization 
 The mechanisms by which photosensitizers preferentially accumulate in tumors 
are not fully understood.  Properties that have been implicated in the selective uptake and 
retention of photosensitizers in tumors include a large interstitial space, leaky vasculature, 
compromised lymphatic drainage, high number of tumor-associated macrophages which 
ingest certain PS, increased number of low density lipoprotein receptors, large amounts 
of newly synthesized collagen, low tissue pH levels, and high lipid content.40,72-74  When 
compared to normal surrounding tissue, acidic tumor pH increases lipophilicity and 
therefore cellular uptake of photosensitizers.75  Intratumoral lipid binds lipophilic 
photosensitizers, and porphyrins have an affinity for newly formed collagen.76,77  
Internalization of photosensitizers by the LDL receptor mediated pathway has been 
demonstrated.78  Tumor cells have higher numbers of LDL receptors on their surfaces, 
potentially associated with their higher requirement for cholesterol than normal cells to 
build membranes.79  Several studies have achieved preferential photosensitizer release to 
tumor cells by associating the photosensitizers with low density lipoproteins and by 
increasing hydrophobicity by augmentation with liposome delivery systems.80-82 
However, other studies have shown that a degree of selectivity does not correlate with 
their hydrophobicity or their affinity for LDL, indicating that the LDL-receptor mediated 
pathway may not be the main route of internalization83,84  
 
e. Photosensitizers 
Porfimer sodium was the first photosensitizer to have received FDA approval for 
treatment of esophageal and endobroncheal cancer, and it is currently used to treat a wide 
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variety of cancers.85  It is synthesized from hematoporphylin and it is composed of 
monomers, dimers, trimers and larger oligoomers.86  Porfimer sodium has 2 major 
disadvantages.  First, it results in prolonged skin photosensitivity lasting for 6 to 8 
weeks.40  Second, activation of porfimer sodium occurs at 630 nm, which limits the depth 
of light penetration in tissue to less than 5 mm.    
 Newer generations of photoactive agents are being developed with reduced risk of 
unwanted side-effects.  Second generation photosensitizers include newer synthetic 
products of various groups (porphines, porphycenes, chlorines, phtalocyanines and 
others) that possess a better pharmacological profile, including more efficient light 
absorption and a higher quantum yield for singlet oxygen.87,88  One such agent, 
verteporfin (Benzoporphyrin derivative monoacid A ring, BPD-MA, Visudyne®), 
synthesized from protoporphyrin, has been approved for the treatment of people with 
macular degeneration.89  Verteporfin is a chlorin-type molecule derived from porphyrine 
and exists as an equal mixture of two regioisomers, BPD-MAC and BPD-MAD. 
Pharmacokinetic studies with intravenous injection showed a t ½ of 5 to 6 hours with the 
drugs distributed particularly to the liver, spleen and kidneys.90  Most of an injected dose 
of verteporfin is cleared within 24 hours in mice.91  Due to its rapid plasma and tissue 
pharmacokinetics, verteporfin results in less skin photosensitivity than do first generation 
photoactive drugs.90,92  In addition, verteporfin has an absorption maximum around 690 
nm, and this wavelength permits activation of the drug within the deeper portions of the 
target tissue than older photoactive agents.   
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f. Light source and delivery 
Lasers are most frequently used for PDT because of their highly coherent monochromatic 
light that can be channeled into quartz fibers used as light delivery devices.  Light is 
usually delivered through fiber-optic cables to the treatment site.  Diode lasers are 
becoming available, replacing the labor intensive argon pumped dye lasers.  Non-
coherent light sources, such as filtered lamps or light emitting diode (LED) arrays have 
also become available for PDT.  These offer several advantages over a laser including 
lower equipment costs, minimal risk of personnel eye damage and no special electrical or 
plumbing requirements.  Limitations of non-choherent light sources include low power 
output and difficulty in launching light into small optical fibers.93  
 The choice of photosensitizer dictates which wavelength of light is required for 
treatment.  For example, porfimer sodium is activated at 630 nm, whereas verteporfin is 
activated at 690 nm.  The depth of penetration of laser light depends on the light’s 
wavelength, on whether the laser is superpulsed, and on the power output.  Light in the 
600-700 nm region of the spectrum penetrates 50-200% more than light in the 400-500 
nm region.94  Pogue et al evaluated average depth of tissue necrosis using BPD-MA with 
irradiation protocol of 50 J cm2 and 200 mW, 690 nm continuous wave produced from an 
argon ion pumped dye laser delivered to a subcutaneous rat prostate model.  The study 
showed an average penetration depth of 8.7 mm.95  The penetration of the light is also 
very much dependent on the type of tissue involved.  Highly pigmented tissues or tissue 
with high hemoglobin content, such as muscle, can reduce the depth that light can 
penetrate.96  
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CHAPTER 2 
EXPERIMENTAL PURPOSE AND HYPOTHESIS 
 
 In PDT, a photosensitizer is typically administered to the patient by intravenous 
injection.  However, intravenous injection of a photoactive drug to a horse is not feasible 
at this time.  Pharmacokinetic, drug distribution, and toxicology studies have not been 
conducted using these agents in horses, and the amount of drug to be delivered would 
likely be excessive in volume and expense.  Additionally, intravenous application of the 
drug can result in sunlight-induced skin photosensitization, requiring horses to remain 
indoors for up to several weeks.  Stall confinement predisposes the equine patient to 
potentially life-threatening maladies including colic and respiratory infection.  At the 
University of Missouri-Columbia, Veterinary Medical Teaching Hospital, we are 
investigating a novel approach to the treatment of equine periocular SCC.  In equine 
patients undergoing local PDT, a photoactive agent is injected locally into the wound bed 
immediately after surgical resection of the tumor followed by light irradiation.97,98  
 A reproducible murine model is essential to prospectively investigate key basic 
science questions regarding the effectiveness of local PDT on SCC.  Reports of 
xenotransplantation of equine tumors are limited to a sarcoid derived cell line and an 
undifferentiated skin carcinoma.28,29  To date, a clinically relevant in vivo model for 
equine SCC does not exist.  In study 1, we examined the ability to cryopreserve ocular 
SCC obtained from 3 affected equine patients and the ability of SCID and nude mice to 
support growth of cryopreserved tumor tissue.  The morphological and histological 
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appearance and characteristic staining for cytokeratin 5/6 and p53 of the cryopreserved 
tissue sections and xenografts in mice were compared with these of the original host 
tumors.   
 In study 2, we developed a nude mouse model, bearing human skin origin SCC.  
Specifically, we report the use of intratumoral injection of verteporfin as a means of drug 
administration for PDT and the efficacy of local PDT on growth inhibition of SCC.  
Response rates with respect to drug dose and type of solvent were compared.  We 
hypothesized that local PDT with verteporfin would result in growth inhibition of 
subcutaneous SCC in a murine model and that response rate would be drug dose 
dependent.  Further, we hypothesized that use of dimethyl sulfoxide (DMSO) as a solvent 
would result in better treatment response rates than use of 5% dextrose solution in water 
(D5W) as a solvent.  
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CHAPTER 3 
 
STUDY 1: DEVELOPMENT OF A MURINE MODEL FOR  
EQUINE OCULAR SQUAMOUS CELL CARCINOMA 
 
MATERIALS AND METHODS 
Animals: 
SCID mice, Fox Chase Outbred female, 4-5 weeks of age, weighing 16 to 20 g, were 
obtained from Charles River Laboratory, MA, USA.  Athymic nude mice, Foxn 1nu 
female, 4-5 weeks of age, weighing 16-20 g, were obtained from Harlan Sprague Dawley, 
IN, USA.  Mice were kept in sterile microisolator cages with autoclaved bedding, placed 
in a laminar air-flow cabinet under specific pathogen-free conditions with a controlled 
temperature of 72 ºF, humidity of 45% and 12-h light cycle.  Animals were given 
autoclaved food and acidified water (pH 2.8) ad libitum.  All manipulations were 
performed in a laminar flow hood under sterile conditions.  Enrofloxacin (West Haven, 
CT) was supplemented in the drinking water (75mg/450 mLs) for 2 weeks following 
tumor implantation.  All animals used in this study were handled in strict adherence to 
institutional Animal Care and Use Committee guidelines and to the ARVO Statement for 
the Use of Animals in Ophthalmic and Vision Research.  
 
Tumor collection and cryopreservation: 
Spontaneously occurring primary ocular SCC was surgically excised from 3 affected 
equine patients at the University of Missouri, College of Veterinary Medicine, Veterinary 
Medical Teaching Hospital (Table 1).  Tumors in each horse were located in the 3rd 
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eyelid, cornea and conjunctiva, originally measuring 1 x 1 x 3 cm, 2.5 x 2 x 0.5 cm and 
1.5 x 1.5 x 0.8 cm in diameter, respectively.  Tumors were handled using sterile 
technique, and sections of each tumor were fixed in 10% sodium phosphate buffered 
formalin for histologic evaluation.  Remaining tumor sections were cut into 1.5 mm3 
cubes and incubated in 10 ml of TL-Hepes buffer solution supplemented with BSA and 
1.5 M dimethylsulfoxide (DMSO, Sigma, MO) for 30 minutes at room temperature. 99  
The tissues and medium were then aspirated into a 0.5-mL freezing straw and cooled 
initially to -7 ºC at a rate of 1 ºC/ min in a programmable freezer (Planer, Model: Kryo 10 
Series II).  At -7 ºC, ice crystallization was initiated by touching the side of the straws 
with a cotton-tipped swab that was soaked in liquid nitrogen.  After a 5-min isothermal 
hold, the cooling rate was decreased to 0.5 ºC/ min.  Once the temperature reached – 55 
ºC, the straws were transferred to liquid nitrogen for storage until implantation.  
 
Cell viability test: 
Cryopreserved equine SCC tissues, stored in liquid nitrogen for approximately 1 year 
were prepared for transplantation by thawing at 20 ºC and washing three times in sterile 
TL-Hepes solution.  Cell viability of the frozen-thawed tissue sections was determined 
with use of ethidium homodimer-1 (13μL/mL) and calcein AM (0.4 μL/mL) fluorescent 
stains (Live/Dead Viability/Cytotoxicity Kit, Molecular Probes; Eugene, OR) and a 
confocal microscope (BioRad Radiance 2000 system coupled to an Olympus IX70 
inverted microscope equipped with Krypton-Argon mixed lasers and a red diode laser). 
Approximately 1.5 mm thickness tumor cross-sections were incubated with the stains in 
phosphate buffered saline for 30 minutes at room temperature.  The numbers of calcein 
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AM stained viable cells (green fluorescence) and ethidium homodimer-1 stained non-
viable cells (red fluorescence) of all sections were objectively evaluated using image 
analysis software (Image-Pro Plus, MediaCybernetics; Carlsbad, CA).  Remaining tissue 
sections were transferred to a stir flask at 37 ºC with 0.2 % trypsin plus 0.2 % collagenase 
to disaggregate into single cells.  Cell viability was also determined on cell suspensions 
with a Trypan blue dye exclusion test.  An equal volume of cell suspension (100μL) and 
0.4 % (w/v) Trypan blue were mixed and loaded onto a hemocytometer to count the cells.  
The proportion of viable cells was determined by comparing the number of non-viable 
cells stained blue by Trypan blue and viable cells which remained clear of the dye.  
 
Transplantation of equine tumor: 
Under general anesthesia with a continuous flow of 100% oxygen containing isoflurane, 
equine tumor sections from 3 horses measuring 1.5 mm in diameter were implanted into 
the dorsal lumbar subcutaneous tissues of the right flanks in 15 athymic nude mice and 
15 SCID mice using a 3-mm microsurgical knife (Surgical Specialties Corp., PA).  Five 
mice of each strain were randomized to receive tumor sections from each of the 3 original 
equine patients.  Transplantation was performed within 20 minutes following thawing of 
the tissues.  A “take” was defined as an increase in volume of the tumor compared to the 
original transplantation.  Mice were evaluated daily, and tumor growth rates were 
calculated after measuring the size of the tumor in three dimensions using Jameson 
calipers.  The tumor volume, V, was calculated using the formula V= (l x w x h) x π/6, 
where l is the longest axis of the tumor, w is the axis perpendicular to l, and h is the 
height of the tumor.  The mice were euthanized by cervical dislocation at day 150, and 
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tumor, lung, liver, kidney, spleen and regional lymph node tissue from xenografted mice 
were harvested and immediately processed as described below.  
 
Histopathological examination: 
Representative tumor sections from 3 original equine patients, cryopreserved tumor tissue 
and tumors from xenografted mice were each fixed in 10% sodium phosphate buffered 
formalin, paraffin embedded and stained with hematoxylin-eosin (H&E).  Morphologic 
features were examined by a board-certified veterinary pathologist (J. Turk), using light 
microscopy.  Additional tumor sections were processed for immunohistochemistry.  
Briefly, tissues were cut at 4 μm and placed on positively-charged slides.  The slides were 
irradiated in a microwave oven (700 W) and left on a 43 ºC slide warmer overnight.  
They were hydrated in graded ethanol and steamed at 95 ºC for 20 min in Citrate Buffer 
(DakoCytomation, Carpinteria, CA) pH 6.0, rinsed, and placed in Tris-buffered saline.  
Slides were treated with 3% H202 for 15 min, washed in buffer, treated with Protein 
Block (DakoCytomation, Carpinteria, CA) for 5 min and drained.  Slides were then 
incubated in mouse anti-Cytokeratin 5/6 antibody (clone D5/16B4, Zymed, South San 
Francisco, CA) or rabbit anti-P53 antibody (SC-6243, Santa Cruz Biotechnology Inc., 
Santa Cruz, CA) for 60 min.  Negative controls were treated with mouse IgG (Sigma, St. 
Louis, MO) for 60 min.  Secondary and tertiary reagents used for cytokeratin stain were 
biotinylated anti-rabbit, anti-mouse and anti-goat immunoglobulins (LSAB2+. 
DakoCytomation, Carpinteria, CA) and streptavidin conjugated to horseradish peroxidase 
(LSAB2+. DakoCytomation, Carpinteria, CA) for 20 min each.  The chromogen used 
was DAB+ (DakoCytomation, Carpinteria, CA.) for 5 min.  The secondary reagent used 
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for p53 stain was rabbit Envision+ (DakoCytomation, Carpinteria, CA) for 30 min.  The 
chromogen used was Nova Red (Vector, Burlingame, CA) for 10 min.  Slides were then 
counterstained in Mayer’s Hematoxylin (Newcomer’s Supply, Appleton, WI) for 1 
minute, dehydrated and cover slipped.  The stained sections were subjectively evaluated 
for the presence, intensity and location of staining.  Lung, liver, kidney spleen and 
regional lymph node tissue from each mouse were evaluated histologically for evidence 
of metastases.   
 
2. RESULTS 
Cell viability 
The effect of cryopreservation on cell viability in frozen-thawed tissue sections from 3 
horses was evaluated with ethidium homodimer-1 and calcein AM fluorescent stains 
(Figure 2).  The mean percentage (± SD) of viable cells indicated by green fluorescence 
for each sample was 63.3 (± 8.8) %.  Non-viable cells were sparsely interspersed among 
live cells with more non-viable cells noted at the periphery of each tissue section.  The 
mean percentage (± SD) of viable cells in cell suspension determined by Trypan blue dye 
exclusion test was 61.5 (± 4.1) %.  
 
Tumor implantation efficiency and growth rate 
Tumor growth was observed in 1 recipient SCID mouse (Figure 3) and 2 nude mice.  
The tumors were well circumscribed solid masses located in the subcutaneous space of 
each mouse.  The latent period between subcutaneous implantation and the first evidence 
of tumor growth ranged between 27 and 29 days.  The tumor reached 2010 mm3 in a 
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SCID mouse at day 150.  The tumors in the nude mice were 1590 mm3 and 879 mm3 at 
day 150.  Tumor doubling time ranged from 5 days (at day 30) to 35 days (at day 90), 
with slower growth rate observed with time (Figure 4).  Mean tumor doubling time was 
14. 5 days.  
 
Histopathologic evaluation 
Histopathologic examination was performed on original equine tumors, cryopreserved 
tumors, and xenografted tumors (Figure 5).  The cut surfaces of the xenografted tumors 
were homogenous grayish-white with focal, yellow, central necrotic areas.  All 
xenografted tumors were well-circumscribed with distinct fibrous capsules and were 
restricted to the subcutaneous space.  Histopathologic evaluation of xenografted tumors 
confirmed well differentiated SCC with multifocal dyskeratosis, keratin pearls, and 1-3 
mitotic figures per 400x field.  There were no marked morphologic differences between 
the primary equine tumors, cryopreserved tumors and xenografted tumors.  Characteristic 
diffuse and strong positive immunoreactivity for cytokeratin 5/6 remained the same in its 
intensity and location after cryopreservation and transplantation (Figure 5).  
Immunoreactivity for p53 appeared as a dark brownish granular signal and was found 
solely in the nucleus, predominantly in the periphery of the neoplastic islands with loss of 
staining toward the keratinized center in excised (Figure 6A), cryopreserved (Figure 6B), 
and transplanted (Figure 6C) ocular SCC.   In all cases, tumors demonstrated only local 
growth without evidence of invasion into lymphatics or blood vessels.  There was no 
evidence of metastases by visual inspection at the time of necropsy or by 
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histopathological examination of lung, liver, kidney, spleen and regional lymph node 
tissue. 
 
3. DISCUSSION 
 Tumor xenografts have been widely used in human medical research using both 
nude and SCID mice.  The absence of functioning cell mediated immunity (T cells) in 
nude mice can permit the growth of xenotransplanted tumor tissues without subsequent 
rejection.  SCID mice lack both functional T and B lymphocytes, eliminating much of the 
compatibility issues associated with host immunity.100   Both athymic nude and SCID 
mice were used as recipients in the present study.  The primary tumor take rate of equine 
SCC for nude and SCID mice was 13% and 7% respectively.  This is compatible with 
previous reports discussing the difficulty in establishing SCC in nude mice. 101,102 
Previously reported take rates of  fresh SCC xenografts were 0% for canine SCC 
transplanted in SCID mice103, 72% for ovine SCC transplanted in athymic nude mice27 
and 50% and 25.9% for human SCC transplanted into SCID and nude mice, respectively. 
104, 105  The tumor xenografts in the present study showed a latent period of 27 to 29 days 
followed by progressive growth with tumor doubling time ranging between 5 days (at day 
30) to 35 days (at day 90).  Although these tumors did not display a typical Gompertzian 
growth pattern with sigmoid-shaped growth curves, slower growth rates were observed at 
the later stages of the study.  It is possible the tumors would have reached their 
Gompertzian plateau phase if the tumors were allowed to grow longer than 150 days.  
 Reported take rates for tumors vary depending on several factors.  The location of 
inoculation impacts take rate with subcutaneous tissue demonstrating a lower take rate 
 - 20 -
compared to intravenous, intracranial, and intraperitoneal implantation.106  Influence of 
the inoculation site was also demonstrated in breast tumors where the tumor could not be 
successfully transplanted to the subcutaneous tissue of nude mice but grew readily when 
transplanted to the mammary fat pad.107  A subcutaneous space was chosen as an 
implantation site for this study because the original tumor was a cutaneous carcinoma, 
and this location provided the most similar microenvironment for the xenotransplanted 
tumors to grow.  In addition, subcutaneous tumors are easily accessible for inspection and 
local treatment, and their response to treatment can easily be measured.  As solid 
cryopreserved tissue sections were used as the tumor source in the present study, 
subdermal implantation would have been difficult to perform.  A dissociated cell 
suspension was considered for use in this study, with subdermal or subcutaneous 
implantation as a means of optimizing vascularization.32  However, this procedure was 
not performed because xenografts derived from cell suspension carry a greater risk of not 
accurately reproducing the biologic and histopathologic characteristics of the original 
tumor.30  
 The ability to successfully transplant tumors also relates to inherent differences in 
the tumor cells themselves and the number of cells implanted.27,108  In general, the take 
rate correlates closely with the invasiveness and metastatic capability of the tumor.106   
Braakhuis et al. (1984) showed higher take rates in poorly differentiated human head and 
neck SCC than moderately and well-differentiated SCC, suggesting that higher 
proportions of stem cells and viable cells present in poorly differentiated SCC may better 
support tumor growth.104  All equine ocular SCC used as tumor sources in this study were 
confirmed to be well-differentiated tumors by histopathology.  In general, equine ocular 
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SCC demonstrates a relatively slow growth rate and a low metastatic rate compared to 
some other equine tumors.  The relatively low take rate in the current study may reflect a 
low growth potential inherent to this tumor type in mice.   
 Successful growth of various xenotransplantated tumors has been reported with 
inoculation of 5 x 104 to 1 x 106 tumor cells.108  In the present study, a minimum of 2 x 
105 viable cells were considered to be present in each implanted tissue section based on 
the size of the tissue and the results of viability tests.  Kopf-Maier et al. (1986) described 
necrosis of the majority of the colon adenocarcinoma cells shortly after 
xenotransplantation, before regeneration and proliferation of tumor cells can occur.109  
The number of transplanted cells in the present study may have been insufficient to 
assure tumor growth in all mice due to cell death in the initial stage immediately 
following transplantation.  
 Regeneration and proliferation of xenotransplanted tumor cells occur only after 
host connective tissue invades the implants; connective tissue serves as a ground 
substance and guides the development of blood vessels which supply required 
nutrients.109  The low take rate in this pilot study may have been associated with 
inadequate production of extracellular matrix or insufficient chemical signals secreted by 
the host stromal cells including angiogenic factors and soluble growth factors.  Based on 
the importance of host stromal cells for tumor growth, injection of cultured fibroblasts 
along with different types of tumor cells has been attempted.110,111  In these studies, a 
significant stimulating effect of the fibroblasts on the tumor take rate was observed when 
the number of tumor cells was below the tumorigenic dose.  Addition of radiation-killed 
tumor cells or a brain-tissue brei at the time of inoculation has also been shown to 
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improve the take rate and growth rate in cases of small viable inoculum or less aggressive 
tumor type.110,112  Tumor growth is believed to be promoted by this “feeder-layer effect” 
due to secretion of angiogenic and growth factors.  Use of such feeder cells may be 
required to improve the take rate for equine ocular SCC in a murine model. 
 The cytotoxic immune response of the host is an important factor in tumor 
rejection.113 Although nude mice lack mature T lymphocytes, other types of cell-
mediated immune responses, such as B cell antibody response, are present.114  Mice with 
immune defects in the function of B cells, NK cells or both, such as SCID mice, are 
generally better hosts in some cases for xenotransplants than nude mice.  The growth of 
xenotransplanted tumors in athymic nude mice is less predictable compared to SCID 
mice.115  In some human tumors, xenografts subcutaneously transplanted into SCID mice 
grow more rapidly, developing larger tumors compared to athymic nude mice.113,116  In 
the present study, no apparent difference in tumor take rate, latent period or growth rates 
were observed between nude and SCID mice.  Based on these findings, the residual 
immune system of the nude mice does not appear to substantially contribute to the 
relatively low take rate observed.   
 The establishment of skin SCC cell lines has been limited by the low success rate 
of in vitro culture.117,118  Although successful culture of normal equine keratinocytes has 
been reported, an equine SCC cell line has not been established to date.119  Human SCC 
cell lines vary in their requirement for a fibroblast feeder layer such as mouse 3T3 cells, 
collagen scaffold, growth factors and hormones to support clonal growth,120,121  and 
alteration in the degree of differentiation in neoplastic keratinocytes under different 
culture conditions has been reported.122,123  In addition, cell lines bear the risk of 
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phenotypic change, taking up foreign DNA and developing mutations in the p53 
gene.118,121,124  With successful cryopreservation, tumor tissues can be thawed and 
implanted on an as-needed basis for development of a tumor model.  Transplantable 
frozen samples provide a readily available tumor source without the need for repeated 
harvesting procedures, continuous animal passage or cell culture.  In addition, 
xenotransplantation of cryopreserved tissue avoids the risks of biological and chemical 
contamination that have been associated with tissue culture.  Furthermore, cryopreserved 
tissues or cell banks could provide sufficient numbers and varieties of tumor types to be 
useful in oncology research. 
 No prior scientific study on the cryopreservation of equine SCC has been reported. 
Comparison of cell survival calculations between those obtained from ethidium 
homodimer-1 and calcein AM fluorescent stains vs. Trypan blue dye exclusion test 
revealed that the assay results were highly correlated.  Over 60% of the cells were viable 
after cryopreservation in our study, which is similar to another study in which 50 to 60% 
post-thaw survival was reported with normal human epidermal keratinocytes.125,126  In 
addition to necrosis immediately subsequent to the freezing and thawing process, 
cryopreservation-induced delayed-onset cell death (CIDOCD)127 and arrest of cell 
division and function have been recently demonstrated.128,129  These reports described cell 
death over a period of up to 24 hours following cryopreservation, indicating that the cell 
survival rates may be overestimated with short-term post-thaw assessment.  The viability 
tests in the present study were performed within 1 hr of thawing and were designed 
primarily to detect damage of the plasma membranes and the enzymatic activity of 
 - 24 -
cytosolic esterase.  Assessment of survival over the initial 24 hours of thawing may 
reveal a contribution of CIDOCD and is warranted.  
 The histological appearance of the xenografted SCC was in full accord with the 
original equine tumors with preservation of characteristic immunohistochemical 
cytokeratin 5/6 staining.  Previous studies showed overexpression of p53 in equine 
periocular SCC suggesting that UV radiation-induced p53 mutation may be one of the 
important factors involved in the pathogenesis of periocular SCC.130  In moderately 
differentiated equine ocular SCC, positive staining reactivity involved most of the tumor 
cells’ nuclei.131  In the present study, similar to previous reports in horses and cattle with 
well-differentiated SCC, positive immunoreactivity was found solely in the nucleus and 
predominantly in the periphery of the neoplastic islands with loss of staining toward the 
keratinized center in excised, cryopreserved, and transplanted ocular SCC.131,132  
Expression of p53 protein was not detected in normal tissues. These findings suggest that 
any alteration in phenotype or cell differentiation was minimal following 
cryopreservation and xenotransplantation, further supporting these methods as useful 
tools in creating a murine model for equine ocular SCC.   
 Most studies using a murine tumor model have focused on the effects of various 
new therapeutic agents or treatment modalities for the particular tumor type.  Studies 
have shown that tumor xenografts in murine models demonstrate clinically relevant 
response rates to various treatments.16  Human bronchial carcinoma xenografts reproduce 
the chemotherapeutic response pattern of their source tumors and thus play an important 
role in the investigation of new chemotherapy agents.133  Equine SCC established with 
transplantation of cryopreserved tissue in the present study maintained and reproduced 
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the original cellular morphology and differentiation indicating that this model may be a 
relevant in vivo system for studying the biology of this important tumor type in veterinary 
ophthalmology.  This model has potential to be used as a preclinical screen for new 
therapeutic agents and treatment modalities for equine ocular SCC.  The low take rate 
observed in the present study may be improved with modification of cryopreservation 
methods, use of fresh tissue samples, or transplantation with feeder cells.  
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CHAPTER 4 
STUDY 2: LOCAL PHOTODYNAMIC THERAPY FOR  
SQUAMOUS CELL CARCINOMA IN A MURINE MODEL 
 
MATERIALS AND METHODS 
Animals 
All animals used in this study were handled in adherence to institutional Animal Care and 
Use Committee guidelines.  Athymic nude mice Foxn 1 nu (Harlan Sprague Dawley, 
Indianapolis, IN),  female, 6 to 8 weeks old, were kept in sterile microisolator cages with 
autoclaved bedding, placed in a laminar air-flow cabinet under specific pathogen-free 
conditions with a controlled temperature of 72 ºF, humidity of 45% and 12-hr light cycle.  
Animals were given autoclaved food and acidified water ad libitum.  All manipulations 
were performed in a laminar flow hood under strict sterile conditions. 
 
Tumor Model 
A-431 human epidermoid SCC cells (American Type Culture Collection, Manassas, VA) 
were maintained in a humidified 5% CO2 atmosphere at 37 ºC, using Dulbecco’s 
modified Eagle medium (American Type Culture Collection, Manassas, VA) 
supplemented with 10% fetal bovine serum (American Type Culture Collection, 
Manassas, VA) and 1% penicillin-streptomycin solution (American Type Culture 
Collection, Manassas, VA).  Upon reaching confluence, cells were trypsinized with 
0.25% trypsin-ethylenediamine tetraacetic acid (Sigma Chemical Co, St Louis, MO).  To 
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accomplish xenografting, 5 x 106 A-431 cells were suspended in 0.1 mL of Dulbecco’s 
phosphate-buffered saline and injected into the dorsal lumbar subcutaneous space of each 
mouse using a 27-gauge hypodermic needle on a tuberculin syringe.  Mice were 
monitored daily and tumor size was assessed by taking three caliper measurements at 
right angles to each other.  Tumor volume was derived by applying the following formula, 
considering the tumor as a hemiellipsoidal mass: volume (mm3) =  π/6 (l x w x h); where 
l = length, w = width, and h = height in millimeters.134  Experiments were initiated once 
tumor volume reached a minimum of 150 mm3.  Average tumor size at the time of local 
PDT was 231 (+/- 59) mm3.  
 
Photosensitizer  
Verteporfin for injection (Visudyne®, Quadra Logic Technologies, Inc., Vancouver, BC, 
Canada) was diluted in sterile water at 2 mg/mL and was further diluted with either 
dimethyl sulfoxide (DMSO) or 5% dextrose in water (D5W) to concentrations of 2 
mg/mL, 0.2 mg/mL and 0.02 mg/mL.  All concentrations were protected from light and 
were used within 4 hours of preparation.  
 
Light delivery device 
Red light at a wavelength of 688 nm +/- 10 nm was delivered by a light emitting diode 
(LED, Quantum Devices Inc, Barneveld, WI).  Irradiance was set at 100 J/cm2 with a 
fluence rate of 200 mW/cm2 for all experiments (duration of delivery per mouse: 8.3 
minutes).  Emission spot size was adjusted using different size stainless steel attachments 
on the LED, in order to minimize illumination of normal tissues around each tumor.   
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Experimental protocol 
Mice were anesthetized using a face mask and non-rebreathing system connected to an 
anesthetic machine that delivered isoflurane in oxygen.  Mice were placed on a heated 
blanket maintained at 37 ºC throughout the treatment.  Verteporfin was injected locally 
into each tumor at a single site using a tuberculin syringe with a 27 G hypodermic needle.  
Tumors were illuminated with red light 5 min after verteporfin administration (Figure 7).  
 
Experiment A: Drug dose evaluation 
In experiment A, the effect of drug dose was evaluated.  Tumor bearing mice were 
randomly divided into 5 groups with 10 mice in each group (Table 2).  Treatment group 
A1 received a dose of 0.01 mg/cm3 tumor volume at concentration of 0.02 mg/mL 
verteporfin in DMSO (0.5 mL/cm3 tumor volume).  Treatment group A2 received a dose 
of 0.1 mg/cm3 tumor volume at concentration of 0.2 mg/mL verteporfin in DMSO (0.5 
mL/cm3 tumor volume).  Treatment group A3 received a dose of 1.0 mg/cm3 tumor 
volume at concentration of 2.0 mg/mL verteporfin in DMSO (0.5 mL/cm3 tumor volume).  
Control groups A4 and A5 received DMSO alone, or light alone respectively.  An 
additional control group A6 (n = 5) received subcutaneous injections of 200 mg 
verteporfin in DMSO without light illumination to investigate toxic effects from the 
photoactive drug alone.  This dose is compatible with 1.0 mg/cm3 dose for an average 
size tumor (200 mm3).  Mice in control group A6 were euthanized 24 hours after 
injection for necropsy.  
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Experiment B: Solvent evaluation 
In experiment B, the effect of solvent was evaluated.  Tumor bearing animals were 
randomly divided into 4 groups with 10 mice in each group (Table 3).  Treatment groups 
B1 and B2 received verteporfin at dose of 0.1 mg/cm3 diluted in D5W and DMSO, 
respectively.  The drug dose was determined based on results on Experiment A. Control 
groups B3 and B4 received D5W alone or DMSO alone, respectively.  All mice were 
exposed to light as previously described.  
 
Evaluation of tumor response 
All mice were monitored daily for overall body condition including appetite, hydration 
status and activity level.  Body weight was measured twice weekly and all tumors were 
measured in 3 dimensions twice weekly to derive tumor volume.  Tumors were observed 
for color change, edema and ulceration.  Mice were euthanized 30 days after the time of 
treatment or when the tumor volume reached 1500 mm3. Necropsy and histopathology 
were performed on mice that died prior to the study end point in group A3 to evaluate the 
cause of death and on mice in group A6 to investigate toxic effects from the drug alone.  
 
Statistical analysis 
The main outcome variable used in data analysis was the relative change in the tumor 
volume (RCTV) following treatment.  This was derived by using the calculation (Vt-
Vo)/Vo, where Vt represents the tumor volume at each measured time point, and Vo 
represents the tumor volume on day 0 (treatment).  This allowed comparison of treatment 
efficacy between tumors regardless of differences in original tumor volume.  Analyses 
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were performed using Wilcoxon Rank Sum test to compare mean RCTV between groups 
at day 13 and 30.  A p value < 0.05 was considered statistically significant.  
 
2. RESULTS 
Local and systemic toxicity 
 All tumors receiving any intratumoral injection developed mild edema extending 
approximately 3 mm into the surrounding tissue and lasting for less than 24 hr.  Those 
tumors receiving verteporfin injection developed a dark green discoloration of the tumor 
which lasted 24-48 hr.  Eschar formation followed by full thickness ulcers developed in 
tumors following PDT in 1 mouse in the treatment group A1, 4 mice in the treatment 
group A2 and 5 mice in the treatment group B1 (Figure 8).  All ulcers were noted 
between 3 and 7 days post-treatment.  Presence of skin ulceration did not adversely affect 
the overall health of mice as assessed by weight gain, appetite and activity level.  Nine 
out of 10 mice in the group receiving 1.0 mg/cm3 verteporfin died within 1 hour 
following light illumination.  Control animals treated with DMSO or D5W without 
verteporfin injection or light alone showed no significant local phototoxic effect.  No 
systemic adverse effects were noted in other treatment or control groups receiving 
subcutaneous injections of 200 mg verteporfin without light illumination.  
 
The effect of drug dose (Experiment A) 
 Tumor volumes over the study period in experiment A are depicted in figure 9.  
Mean relative change in tumor volume (RCTV) for each group in experiment A at day 13 
and 30 are shown in figures 11 and 12.  No data for treatment group A3 were available 
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for analysis, due to loss of 9/10 mice shortly after the treatment.  For mice that survived 
the peri-treatment period, local PDT of tumors resulted in significant alterations in tumor 
growth and size at day 13 and 30.  By day 13, low dose verteporfin treatment (A1: mean 
RCTV = 1.381 +/- 0.741) significantly inhibited tumor growth as compared to the control 
group A5 (mean RCTV = 3.058 +/- 1.187), but not compared to the control group A4 
(mean RCTV = 1.512 +/- 1.165) with p values of 0.005 and 0.739, respectively.  The 
moderate dose verteporfin treatment (A2: mean RCTV = -0.118 +/- 0.74) resulted in 
significant reduction of tumor growth compared to both control groups A4 (p = 0.0006) 
and A5 (p = 0.0007).  Additionally, mice in the moderate dose treatment group A2 had a 
significantly reduced RCTV compared to the low dose treatment group A1 (p=0.0003).  
By day 30, there was no statistically significant difference in mean RCTV between low 
dose treatment group A1 (mean RCTV =4.228 +/- 2.049) and either control group A4 
(mean RCTV = 6.231 +/- 5.454) or A5 (mean RCTV = 7.384 +/- 3.449) with p values of 
0.429 and 0.032, respectively.  Mean RCTV was significantly smaller in the moderate 
dose treatment group A2 (mean RCTV=1.642 +/- 2.47) compared to both control groups 
A4 and A5, with p values of 0.005 and 0.004, respectively.  Again at day 30, mice in the 
moderate dose treatment group A2 had a significantly reduced RCTV compared to the 
low dose treatment group A1 (p=0.009). 
 The five mice treated with verteporfin and no light (A6) and five of nine mice that 
died acutely after local PDT in high dose treatment group A3 underwent necropsy 
examination.  Segmental jejunal mucosal and serosal hemorrhage and meningeal 
hemorrhage were observed on gross necropsy in 3 mice in treatment group A3.  
Histologic examination of liver, kidney, lung, spleen and brain revealed that all mice in 
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treatment group A3, but none in control group A6, had multiple fibrin clots within the 
pulmonary vasculature.  Congestion and hemorrhage within the GI tract, brain 
parenchyma and cerebral ventricular system were observed in mice in treatment group 
A3 but not in those of control group A6.  
 
The effects of drug solvent (Experiment B) 
 Tumor volumes over the study period in experiment B are depicted in figure 10.  
Mean relative change in tumor volume for each group in experiment B at day 13 and 30 
are shown in figures 13 and 14.  By day 13, treatment with verteporfin in D5W (B1: 
mean RCTV = -0.271 + 0.677) significantly inhibited tumor growth as compared to the 
control group B3 (mean RCTV = 0.618 +/- 1.107) with p value of 0.049.  Treatment with 
verteporfin in DMSO (B2: mean RCTV = -0.258 +/- 0.74) resulted in significant 
reduction of tumor growth compared to the control group B4 (mean RCTV= 1.512 +/- 
1.165) with p value of 0.0006.  By day 30, there was no statistical difference in RCTV 
between D5W treatment group B1 (mean RCTV = 2.326 +/- 3.746) and D5W control 
group B3 (mean RCTV = 4.128 +/- 8.404) (p = 0.4179).  Statistically significant 
inhibition of tumor growth persisted in the DMSO treatment group B2 (mean RCTV = 
1.538 +/- 2.47) compared to DMSO control group B4 (mean RCTV = 6.231 +/- 5.454) 
with p value of 0.0053.  There was no statistical difference in mean RCTV between 
group B1 and B2 at both day 13 and 30 with p values of 0.396 and 0.561, respectively.  
 Complete tumor remission was achieved in 2 mice in treatment group B2 (Figure 
15).  Tumor volumes at the time of treatment for these mice were 307.72 mm3 and 234.45 
mm3, respectively (average size of original tumors for treatment group = 195.28 mm3).  
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The time at which complete tumor remissions occurred was 20 and 30 days post-
treatment respectively.  At the light dose used in this experiment, no significant local 
phototoxic effects were noted in groups that did not receive verteporfin or solvent. 
 
3. DISCUSSION 
 Verteporfin is a cholorine-type second generation photosensitizer, now approved 
in many countries for the treatment of age-related macular degeneration.  Second 
generation drugs possess a better pharmacological profile than the first generation drugs, 
including more efficient light absorption and a higher quantum yield for singlet 
oxygen.87,88  Verteporfin was chosen as the photoactive agent in the present study, due to 
its desirable properties including a short photosensitivity period of only a few days, and a 
strong absorption peak at 688 nm, giving better depth of light penetration in tissue.135  
The reported PDT protocol with verteporfin in people and animals consists of systemic 
administration of verteporfin at doses of 0.5 to 2.0 mg/kg body weight, followed by 
exposure of target lesions to 40 to150 J/cm2 of photoradiation at 690 nm.92,136,137  A 
complete clinical response rate of 95% has been reported in nonmelanoma skin cancers, 
including SCC in people treated with PDT using verteporfin administered intravenously 
with a drug dose of 0.6 mg/kg and a light dose of 180 J/cm2.92  Local PDT entailing 
intratumoral injection of photoactive agents reported in subcutaneously implanted mouse 
glioma and mammary adenocarcinoma using a hematoporphyrin derivative suggested 
that selectivity and efficiency of PDT may be enhanced with local administration of 
photosensitizers.138,139   
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 The present study demonstrates that local photodynamic therapy with verteporfin 
at dose of 0.1 mg/cm3 tumor volume effectively inhibited the growth of subcutaneous 
SCC in a murine model.  No significant effect on tumor growth occurred in animals that 
received solvent alone or light alone.  Verteporfin administered locally at a dose of 0.1 
mg/cm3 tumor volume in our murine model attained equivalent body weight doses of 0.5 
to 1.0 mg/kg.92,136,140,141  This dose was compatible with previously reported successful 
treatment of SCC in humans with systemic administration of verteporfin.92,136,138  In one 
murine model of mammary adenocarcinoma, intratumoral injection of porfimer sodium 
has been reported to result in 15 times higher porphyrin levels in tumor and 10 times 
greater rate of tumor mitochondrial enzyme inhibition compared to systemic injection, 
suggesting that local PDT may require a lower total dose of drug per patient.138  However, 
in the current study, local PDT using the lower dose of verteporfin (0.01 mg/cm3) was not 
shown to be effective in inhibiting the growth of SCC.  This may be due to inadequate 
vascular effects elicited by local injection of the photosensitizer or presence of DMSO in 
the solvent preventing pathologies elicited by free radicals and reactive oxygen species. 
142  Other factors that have also been reported to influence the response to PDT and 
chemotherapy include cellular glutathione S transferases and glutathione protecting cells 
from reactive free radicals. 142,143 
 Local PDT with verteporfin at dose of 1.0 mg/cm3 resulted in significant mortality 
in our murine model; thus, dose effects on tumor growth inhibition could not be 
determined.  Although no morbidity has ever been reported in people, severe 
cardiovascular complication and acute lethality following PDT have been documented in 
other species, including mice and cats.144,145  In that report, the histological findings were 
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consistent with a systemic shock reaction; release of endogenous vasoactive mediators 
was speculated to be the likely cause of death.144  Histopathology of the mice that died 
shortly after receiving our highest drug dose in the present study revealed multi-organ 
congestion and hemorrhage within gastrointestinal tract, brain parenchyma and cerebral 
ventricular system in conjunction with pulmonary fibrin clots, suggestive of disseminated 
intravascular coagulopathy (DIC).  The relationship of PDT treatment area to total body 
area has been suggested as an important parameter in the induction of acute lethality in 
murine models.  In the current study, the average tumor area was 68.1 mm2 
(approximately 10% of the average mouse body surface area) for the group that received 
high dose verteporfin (1.0 mg/cm3).  Although a large tumor occupying as much as 10 % 
of the total body surface area in any species is unlikely to be treated with PDT alone, 
acute destruction of tissue mass of this size can potentially result in systemic shock 
reaction or DIC and should be considered.  None of the mice that received verteporfin at 
a dose of 1.0 mg/cm3 without light illumination developed any signs of systemic toxicity, 
suggesting that the high lethality in the 1.0/cm3 dose group was likely associated with a 
PDT reaction rather than a response to the verteporfin itself.   
 Singlet oxygen has a short radius of action (10-20 μm), therefore, complete and 
homogenous distribution of the photosensitizer in the tumor is essential for effective 
tumor destruction with local PDT.40  Studies have demonstrated that porfimer sodium, 
injected directly into the center of the subcutaneous glioma and bladder tumors, was 
retained and distributed throughout the entire tumor.139,146  In addition, intratumoral 
administration yielded a much higher level of photosensitizer in tumor tissues and lower 
levels in normal tissues including the skin and other organs.147  In the present study, 
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DMSO was compared to D5W as a solvent for verteporfin. DMSO is readily permeable 
to biological barriers including mucous membranes, cell and organelle membranes, and is 
widely used in veterinary medicine as an agent that enhances drug absorption across the 
skin.148-150  We hypothesized that DMSO would increase local diffusion of verteporfin 
into solid SCC tumors, therefore resulting in better tumor growth inhibition.  The final 
DMSO concentration used in the present study was 85.6%, which was considered to be 
sufficient to provide effective drug penetration based on previous studies.150-152  However, 
there was no statistically significant difference in mean RCTV at a dose of 0.1 mg/cm3 
dose groups using DMSO or D5W.   
 Complete tumor regression was obtained in 2 mice that received verteporfin at a 
dose of 0.1 mg/cm3 dissolved in DMSO. Interindividual variability in response rates 
observed in the current study may be associated with inconsistent and incomplete 
diffusion of the drug within the tumor. Longer time periods between injection and light 
illumination may allow better distribution of the photoactive agent and improve tumor 
destruction.  Further investigation is warranted to identify the effect of DMSO on 
photosensitizer distribution and cellular localization as a function of time following local 
injection to determine the ideal drug-light interval.  Other important properties of DMSO 
include its free radical scavenging capabilities and anti-inflammatory effects.148,150   
DMSO may have protected treated cells via detoxification of cytotoxic species, masking 
the potential beneficial effects of DMSO in drug distribution.  
 One of the primary factors that affect the efficacy of PDT is the depth of tumor 
from the incident surface of light illumination.  The light wavelength required for PDT is 
dictated by the type of photosensitizer, and tissue penetration of light is directly 
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proportional to its wavelength.153  PDT using porfimer sodium and a 630 nm laser at 
irradiation doses of 50 and 200 J/cm2 has been reported to induce anti-tumor activity to a 
depth of 4.1 to 9.4 mm, respectively.154  Therefore, we speculated that PDT using 
verteporfin and 690 nm light irradiation at 100 J/cm2 might induce anti-tumor activity to 
a depth of more than 10 mm.  The height of all tumors in the present study prior to the 
treatment was less than 10 mm.  However, light transmission through living tissue is 
complex, influenced by tissue heterogeneity, stromal tissue density, tissue oxygenation 
and necrosis.155  Relatively high stromal tissue density of SCC may have reduced the 
light penetration, leading to incomplete destruction of larger tumors.  Two tumors that 
completely regressed in the present study had tumor volume of 307.72 mm3 and 234.45 
mm3.  These tumors were larger than the average tumor size, suggesting that tumor 
volume may not be a major factor in treatment efficacy when treating small tumors less 
than 10mm in diameter.  For larger equine periocular tumors, use of interstitial irradiation 
or surgical debulking prior to local PDT should provide adequate light penetration and 
more favorable long term prognosis.  
 Light dose and fluence rate also influence the efficacy of PDT.  Light dose refers 
to the amount of light delivered to a given area and fluence rate refers to the rate of 
delivery.  In a fibrosarcoma murine model and in cats with cutaneous SCC treated with 
PDT, depth of tumor necrosis and therapeutic outcome were found to be logarithmically 
proportional to increasing light energy delivered per unit area.156,157   Synergistic 
enhancement of PDT by hyperthermia, associated with higher fluence rates, was 
suggested as the potential cause of improved therapeutic outcomes.157   However, higher 
fluence rates may also lead to photochemical depletion of ambient tumor oxygen in some 
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cases, thus causing acute hypoxia and limiting treatment effectiveness.158  In a murine 
fibrosarcoma model, PDT with light dose of 100 J/ cm2 at fluence rate of 30 mW/ cm2 
resulted in significantly longer median tumor remission rates than PDT at 100 J/cm2 and 
150 mW/cm2 demonstrating that in some cases, lower fluence rate can improve PDT 
response.158  Light dose used in the current study was 100 J/cm2 and fluence rate was 200 
mW/cm2 (total delivery time = 8.3 minutes).  A higher light dose and lower fluence rate 
might have resulted in additional tumor growth inhibition and potentially better complete 
tumor regression rates.   
 A LED used as a light source in the present study generates less coherent light 
than a laser, but has a fairly narrow bandwidth.  A LED offers several advantages over a 
laser including lower equipment costs, minimal risk of personnel eye damage and no 
special electrical or plumbing requirements.  In addition, the LED probe does not require 
a fiber optic, which can create a substantial loss of power between the laser light source 
and the target tissue for light delivery.  Successful application of PDT with a LED has 
been described for SCC in cats and humans.159,160  Although a direct comparison between 
LED and laser cannot be made in this study,  our results suggest that using a LED light 
source can be useful in local PDT for SCC, representing a cost-effective alternative to 
medical lasers.   
 A human SCC nude mouse xenograft was used as an equine tumor model in the 
present study.  To date, a commercially available equine SCC cell line does not exist.  
We have previously reported on the development of equine ocular SCC by 
xenotransplantation of cryopreserved equine tumor sections.161  These equine xenografted 
tumors maintained and reproduced their original cellular morphology and differentiation, 
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indicating the model may be a relevant in vivo system for studying the biology of this 
tumor type.  However, the low take rate of that tumor model limited its use in the present 
studies.  There may be differences in drug diffusion, absorption and overall effect of local 
PDT in other species affected by SCC, due to potential difference in immune responses 
elicited by PDT, and in glutathione level, vascularity, tumor pH, LDL and 
benzodiazepine receptor number in the tumor.  
 This study documents the first report of epidermal SCC treated with local PDT in 
a murine model.  Results indicate that SCC can be effectively inhibited by local PDT.  
While our follow-up periods are relatively short, results obtained from this study indicate 
that tumor growth of SCC can be effectively inhibited using intratumoral injection of 
verteporfin.  Additional studies are currently underway, examining differences in light 
dose and treatment response rates.  Local PDT combined with surgical debulking has the 
potential of being used as a curative modality in horses affected by localized cutaneous 
SCC.  
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TABLES 
 
 
Table 1. Origin of equine SCC tumors 
 
 Signalment Tumor Origin Xenograft 
take rate 
Tumor 1 Appaloosa 
12-year old mare 
Cornea 1/15 (6.6%) 
SCID mouse 
Tumor 2 Missouri Fox  Trotting 
 Horse 
11-year-old gelding 
Third eyelid 1/15 (6.6%) 
Nude mouse 
Tumor 3 Thoroughbred 
20-year-old mare 
Bulbar conjunctiva 1/15 (6.6%) 
Nude mouse 
 
    
 
 
 
 
Table 2. Experiment A – effect of photoactive drug dose 
 
 Verteporfin dose 
(mg/cm3) 
Solvent 
Treatment group A1 0.01 DMSO 
Treatment group A2 0.1 DMSO 
Treatment group A3 1.0 DMSO 
Control group A4 None DMSO 
Control group A5 None None 
Control group A6 0.1 DMSO 
 
    
 
 
 
 
Table 3. Experiment B – effect of solvent 
 
 Verteporfin dose 
(mg/cm3) 
Solvent 
Treatment group B1 0.1 D5W 
Treatment group B2 0.1 DMSO 
Control group B3 No drug D5W 
Control group B4 No drug DMSO 
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FIGURES 
 
Figure 1. Jablonski diagram 
3P* triplet excited state photosensitizer, S oxidized substrate, 3O2 triplet ground state 
oxygen, O2- superoxide anion, O2  superoxide radical, P+ oxydized photosensitizer, 1O2 
singlet state oxygen. 
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 Figure 2. Confocal microscopy images of cryopreserved equine ocular SCC  
 from one of the original equine patients, x 4 (A) , x 30 (B). 
 
 
 
Figure 3. The SCID mouse bearing equine SCC 138 days following implantation. 
 
 
Figure 4. Growth curve of xenotransplanted equine SCC 
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Figure 5. Histopathology of SCC from an original equine patient, H&E stain, x 400(A), 
immunohistochemical staining for cytokeratin 5/6 on SCC from an original equine 
patient, x 400 (B), histopathology of cryopreserved equine SCC, H&E stain, x 400(C), 
immunohistochemistry staining for cytokeratin 5/6 on a cryopreserved equine SCC, x 400 
(D), histopathology of an equine xenograft harvested on day 150 from a SCID mouse, 
H&E stain, x 400 (E), immunohistochemical staining for cytokeratin 5/6 on a SCC 
xenograft, x 400 (F) 
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Figure 6.  Immunoreactivity for p53 on original (A), cryopreserved (B), and transplanted 
(C) ocular SCC. Nonimmune control (D).  
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 Figure 7. A photograph of a xenografted nude mouse under general anesthesia  
 being illuminated with LED light after local injection with verteporfin. 
 
 
 
 
 
 
 
 
 Figure 8. Photographs of an ulcer formed in the treatment site following PDT 
 with local injection of verteporfin at a dose of 0.1 mg/cm3.  
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Figure 9. Comparison of tumor growth in experiment A. 
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Figure 10. Comparison of tumor growth in experiment B. 
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Figure 11.  Experiment A. Mean relative change in tumor volume at day 13. 
 
 
 
 
Figure 12. Experiment A. Mean relative change in tumor volume at day 30. 
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Figure 13. Experiment B. Mean relative change in tumor volume at day 13. 
 
 
 
 
 
Figure 14. Experiment B. Mean relative change in tumor volume at day 30. 
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Figure 15.  A Photograph of a mouse in treatment group B2 demonstrating complete 
regression of SCC.  The mouse here, had an initial tumor of 234.45 mm3 at the time of 
treatment and was observed to be free of any gross evidence of SCC at day 20 (inset). 
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